Search research articles
Contact Us
Filters
Showing results (201-210 of 418) with videos related to
Page
of 42
Sort By:
Cancer
|
October 5, 2017
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors
Philippe L Bédard, Michael A Davies, Scott Kopetz, et al.
Journal of the National Cancer Institute
|
February 7, 2016
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
Francesco Sabbatino, Yangyang Wang, Giosuè Scognamiglio, et al.
Science Signaling
|
September 3, 2015
The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth
Juxiang Cao, Xiangpeng Dai, Lixin Wan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
The Oncologist
|
February 24, 2019
Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control
Christopher Alvarez-Breckenridge, Anita Giobbie-Hurder, Corey M Gill, et al.
Cancer Research
|
October 3, 2007
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation
John P Plastaras, Seok-Hyun Kim, Yingqiu Y Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2007
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H Vonderheide, Keith T Flaherty, Magi Khalil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2009
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers
Erica L Carpenter, Rosemarie Mick, Andrew J Rech, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Georgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Journal for Immunotherapy of Cancer
|
February 23, 2022
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
Siming Li, Xiaowen Wu, Xieqiao Yan, et al.
Page
of 42
Search research articles
Search
Showing results (201-210 of 418) with videos related to
Sort By:
Page
of 42
Cancer
|
October 5, 2017
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors
Philippe L Bédard, Michael A Davies, Scott Kopetz, et al.
Journal of the National Cancer Institute
|
February 7, 2016
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
Francesco Sabbatino, Yangyang Wang, Giosuè Scognamiglio, et al.
Science Signaling
|
September 3, 2015
The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth
Juxiang Cao, Xiangpeng Dai, Lixin Wan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
The Oncologist
|
February 24, 2019
Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control
Christopher Alvarez-Breckenridge, Anita Giobbie-Hurder, Corey M Gill, et al.
Cancer Research
|
October 3, 2007
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation
John P Plastaras, Seok-Hyun Kim, Yingqiu Y Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2007
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H Vonderheide, Keith T Flaherty, Magi Khalil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2009
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers
Erica L Carpenter, Rosemarie Mick, Andrew J Rech, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Georgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Journal for Immunotherapy of Cancer
|
February 23, 2022
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
Siming Li, Xiaowen Wu, Xieqiao Yan, et al.
Page
of 42